R. Milasiene

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

P. Emery, J. Vencovský, A. Sylwestrzak, 2015, Annals of the rheumatic diseases.

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

R. Collins, C. Gordon, D. Isenberg, 2016, Arthritis & rheumatology.

Evaluation of antioxidactivity of green and black tea (Camellia sinensis) and rooibos (Aspalathus linearis) tea extracts by means of hplc with reaction detector

A. Maruška, M. Ligor, R. Milasiene, 2007 .

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

P. Emery, J. Vencovský, A. Sylwestrzak, 2017, Rheumatology.

FRI0128 A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-Week Results)

P. Emery, J. Vencovský, A. Sylwestrzak, 2015 .